{
  "ticker": "NBIX",
  "company_name": "Neurocrine Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT06911112",
      "title": "NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Major Depressive Disorder",
      "start_date": "2025-03-31",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT07105111",
      "title": "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor",
      "status": "RECRUITING",
      "phase": "PHASE4",
      "condition": "Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia",
      "start_date": "2025-08-29",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT03065192",
      "title": "Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders",
      "start_date": "2017-05-11",
      "completion_date": "2021-08-10",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT05859698",
      "title": "Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia",
      "status": "COMPLETED",
      "phase": "PHASE4",
      "condition": "Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia",
      "start_date": "2023-05-09",
      "completion_date": "2024-12-27",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT02405091",
      "title": "Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Tardive Dyskinesia",
      "start_date": "2015-03",
      "completion_date": "2017-03",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT06786624",
      "title": "Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Major Depressive Disorder",
      "start_date": "2025-01-22",
      "completion_date": "2027-07",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT06966401",
      "title": "Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Major Depressive Disorder",
      "start_date": "2025-04-16",
      "completion_date": "2030-05",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT01393600",
      "title": "NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Tardive Dyskinesia",
      "start_date": "2011-08",
      "completion_date": "2012-02",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT03792672",
      "title": "A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2019-02-11",
      "completion_date": "2019-06-18",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    },
    {
      "nct_id": "NCT00232167",
      "title": "Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression",
      "status": "TERMINATED",
      "phase": "PHASE3",
      "condition": "Insomnia, Depression",
      "start_date": "2005-11",
      "completion_date": "2006-04",
      "enrollment": 0,
      "sponsor": "Neurocrine Biosciences"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE3": 16,
      "PHASE4": 3,
      "PHASE1": 12,
      "PHASE2": 17,
      "NA": 1,
      "": 1
    },
    "by_status": {
      "RECRUITING": 8,
      "COMPLETED": 26,
      "TERMINATED": 7,
      "ENROLLING_BY_INVITATION": 1,
      "ACTIVE_NOT_RECRUITING": 2,
      "WITHDRAWN": 1,
      "UNKNOWN": 1,
      "NOT_YET_RECRUITING": 4
    },
    "active_trials": 11,
    "completed_trials": 26,
    "conditions": [
      "Bipolar I Disorder, Mania",
      "Chorea, Huntington",
      "Congenital Adrenal Hyperplasia",
      "Drug-Induced Movement Disorder",
      "Dyskinesia, Cerebral Palsy",
      "Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects",
      "Focal Onset Seizure, Focal Onset Epilepsy",
      "Folliculogenesis",
      "Healthy",
      "Healthy Volunteers",
      "Healthy Volunteers, Schizophrenia",
      "Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders",
      "Insomnia",
      "Insomnia, Depression",
      "Major Depressive Disorder",
      "Parkinson Disease",
      "Parkinson's Disease",
      "SCN8A Developmental and Epileptic Encephalopathy Syndrome",
      "Schizophrenia",
      "Schizophrenia, Cerebellar Ataxia",
      "Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia",
      "Tardive Dyskinesia",
      "Tardive Dyskinesia (TD)",
      "Tourette Syndrome",
      "Type 1 Diabetes Mellitus"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:20:14.151610",
    "search_query": "Neurocrine Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Neurocrine+Biosciences,+Inc."
  }
}